Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer

OBJECTIVES:

Primary

• Evaluate the effect of first-line chemotherapy on expression of hormone receptors and biomarkers in women with metastatic breast cancer.

Secondary

• Assess changes in HER1 and HER2 expression during treatment.

OUTLINE: This is a multicenter study.

Patients receive 6-9 courses of front-line chemotherapy according to the investigator. Patients with estrogen receptor- and/or progesterone receptor-positive disease receive hormone therapy.

Patients undergo biopsy prior to and after completion of chemotherapy for examination of hormone receptors and HER1 and HER2 expression.

After completion of study treatment, patients are followed every 6 months for 5 years.

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the breast

• Metastatic disease
• No inflammatory breast cancer
• Measurable disease according to RECIST criteria
• Hormone receptor status:

• Estrogen receptor- and/or progesterone receptor-negative by IHC

PATIENT CHARACTERISTICS:

• Menopausal status not specified
• WHO performance status 0-2
• Life expectancy > 3 months
• ANC > 1.5 x 10^9/L
• Platelet count > 100 x 10^9/L
• Liver transaminases ≤ 3 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 3 times ULN
• Bilirubin ≤ 1.5 times ULN
• Creatinine ≤ 2 times ULN
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No allergy to xylocaine
• No heart failure, or kidney, bone marrow, respiratory, or liver insufficiency

PRIOR CONCURRENT THERAPY:

• No prior first-line treatment for metastatic disease